Fig. 1 · Structure

Documents & Downloads

Dactolisib Tosylate

Cat. No. A11327 CAS 1028385-32-1

dual PI3K and mTOR kinase inhibitor

Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
p110α IC50 4 nM
p110α-H1047R IC50 4.6 nM
p110α-E545K IC50 5.7 nM
p110γ IC50 5 nM
p110δ IC50 7 nM
p110β IC50 75 nM
mTOR IC50 20.7 nM
mTORC1  
mTORC2
Autophagy

10 targets · Scroll to view more

Dactolisib Tosylate Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Dactolisib Tosylate from 3 published references. In vitro models include A427 cells; human pancreatic CSCs.

Dactolisib Tosylate In Vitro Studies

In A427 cells, Dactolisib abrogated VEGFA upregulation measured by supernatant ELISA. In human pancreatic CSCs, Dactolisib induced expression of 18 miRNAs and inhibited expression of 9 miRNAs compared with control. In Huh-7 cells, Dactolisib treatment increased IL-6 protein expression measured by ELISA. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Dactolisib abrogates VEGFA upregulation in lung cancer cells

Cell-based study · A427 cells [1]

A427 cells were treated with Dactolisib at 1 µM for 24 h, with DMSO as control. Supernatant ELISA measurements showed that treatment abrogated VEGFA upregulation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ELISA-measured VEGFA levels in the supernatantReported result abrogated the VEGFA upregulation[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
24 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Dactolisib

The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.

Results > Targeting LAT1/mTOR overcomes wild-type KRAS-induced resistance (S85); Fig. 6 legend (S424)

ELISA-measured VEGFA levels in the supernatant: ELISA-measured VEGFA levels in the supernatant; comparator: DMSO — Results > Targeting LAT1/mTOR overcomes wild-type KRAS-induced resistance (S85); Fig. 6 legend (S424)

Dactolisib alters miRNA expression in human pancreatic CSCs

Cell-based study · human pancreatic CSCs [2]

Human pancreatic CSCs were treated with Dactolisib at 1 μM for 36 h. Compared with control, miRNA array analysis showed induced expression of 18 miRNAs and inhibited expression of 9 miRNAs.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
miRNA array (Affimetrix gene Chip) analysismiRNA expression induced the expression of 18 miRNAs and inhibited the expression of 9 miRNAs[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
36 h
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Dactolisib; Compound label in the paper: NVP-BEZ 235

The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.

RESULTS > Regulation of microRNA network by NVP-BEZ-235 and/or NVP-LDE-225 in human pancreatic cancer stem cells (S86); Figure 5 legend (S281, S282, S283)

miRNA array (Affimetrix gene Chip) analysis: miRNA array (Affimetrix gene Chip) analysis; comparator: control — RESULTS > Regulation of microRNA network by NVP-BEZ-235 and/or NVP-LDE-225 in human pancreatic cancer stem cells (S86); Figure 5 legend (S283)

Dactolisib increases IL-6 protein expression in Huh-7 cells

Cell-based study · Huh-7 cells [3]

Huh-7 cells were pre-treated with Dactolisib at 100 nM for 24 h, with an untreated group as control. ELISA measurements showed increased IL-6 protein expression in treated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IL-6 protein levels in HCC cells measured by ELISAReported result expression of the IL-6 protein increased in HepG2 and Huh-7 cells treated with NVP-BEZ235[3]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
24 h
Method
pre-treated
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Dactolisib; Compound label in the paper: NVP-BEZ 235

The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.

Materials and methods > Reagents (S4); Materials and methods > Enzyme-linked immunosorbent assay (S47); Results > NVP-BEZ235 increases the expression of IL-6 (S75); Fig. 3 legend (S128)

IL-6 protein levels in HCC cells measured by ELISA: IL-6 protein levels in HCC cells measured by ELISA; comparator: untreated group — Results > NVP-BEZ235 increases the expression of IL-6 (S75); Fig. 3 legend (S128)

Dactolisib Tosylate In Vivo Studies

Male mice in a murine HCC model received Dactolisib at 60 mg/kg/day by i.p. injection. The comparison isolating the compound effect showed a ratio of Ki-67-positive cells in liver tumour lesions of 39.92 ± 2.49 (%) with Dactolisib versus 54.70 ± 3.53 (%) in control. [3]

Dactolisib lowers Ki-67 positivity in murine liver tumours

Animal study · male C57BL6/J mice; murine HCC model [3]

Male mice in a murine HCC model received Dactolisib at 60 mg/kg/day by i.p. injection. In the comparison isolating the compound effect, the ratio of Ki-67-positive cells in liver tumour lesions was 39.92 ± 2.49 (%) with Dactolisib versus 54.70 ± 3.53 (%) in control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ratio of Ki-67-positive cells in the liver tumour lesionsKi-67-positive cells 39.92 ± 2.49 (%)[3]

Conditions shared by the study groups

Route
i.p. injected
Treatment course
Days 14-20; euthanized 6 weeks after oncogene transfection
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dactolisib 60 mg/kg/daycontrol54.70 ± 3.53 (%) control; 39.92 ± 2.49 (%) NVP-BEZ235[3]
Dactolisib 60 mg/kg/day
Model: male C57BL6/J mice; murine HCC model
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Dactolisib; Compound label in the paper: NVP-BEZ 235

The paper names Dactolisib without stating the salt or form; not verified as the tosylate form supplied as A11327. No dose conversion or lot validation.

Materials and methods > Reagents (S8); Materials and methods > Experimental animals (S12); Results > NVP-BEZ235 combined with IL-6 antibody effectively inhibits tumour progression and prolongs the survival time of HCC (S106, S107, S115); Fig. 7 legend (S142, S143, S144)

ratio of Ki-67-positive cells in the liver tumour lesions: ratio of Ki-67-positive cells in the liver tumour lesions; comparator: control — Results > NVP-BEZ235 combined with IL-6 antibody effectively inhibits tumour progression and prolongs the survival time of HCC (S115)

Dactolisib 60 mg/kg/day · Materials and methods > Reagents (S8); Results > NVP-BEZ235 combined with IL-6 antibody effectively inhibits tumour progression and prolongs the survival time of HCC (S115); Fig. 7 legend (S143, S144)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1028385-32-1
Applications dual PI3K and mTOR kinase inhibitor
Formula C37H31N5O4S
Molecular Weight 641.74
Synonyms BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate)
SMILES
CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Dactolisib Tosylate Research References

  1. [1] Ivanisevic T, Ma Y, Van Boxel E, et al. Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation. Nat Commun (2025). PMID: 41397976 DOI: 10.1038/s41467-025-67109-5 Source material
  2. [2] Sharma N, Nanta R, Sharma J, et al. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget (2015). PMID: 26451606 DOI: 10.18632/oncotarget.5055 Source material
  3. [3] Wang Y, Miao X, Jiang Y, et al. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma. Cell Death Dis (2022). PMID: 35165269 DOI: 10.1038/s41419-022-04583-5 Source material

Added to your cart

View Cart Checkout
Loading...